C4 Therapeutics, Inc.
CCCC
$2.61
-$0.08-2.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -104.99M | -119.08M | -111.58M | -103.28M | -105.32M |
| Total Depreciation and Amortization | 1.96M | 2.01M | 1.99M | 1.83M | 1.82M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.62M | 37.77M | 30.33M | 30.65M | 30.69M |
| Change in Net Operating Assets | -29.28M | -15.18M | -8.15M | -9.53M | 7.65M |
| Cash from Operations | -98.69M | -94.48M | -87.41M | -80.32M | -65.16M |
| Capital Expenditure | -607.00K | -592.00K | -168.00K | -180.00K | -180.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.99M | 86.39M | 82.05M | 31.43M | -51.09M |
| Cash from Investing | -8.60M | 85.80M | 81.88M | 31.25M | -51.27M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 126.32M | 7.74M | 10.41M | 10.54M | 45.15M |
| Repurchase of Common Stock | -193.00K | -179.00K | -240.00K | -240.00K | -194.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 274.00K | 274.00K | 407.00K | 407.00K | 382.00K |
| Cash from Financing | 126.40M | 7.84M | 10.57M | 10.71M | 45.34M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.10M | -840.00K | 5.04M | -38.37M | -71.09M |